X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Rezolute candidate RZ358, which is an insulin receptor allosteric site activator. Currently, it is being evaluated in the preclinical trial studies for the treatment of Non-Islet Cell Tumor Hypoglycemia.
Lead Product(s): Ersodetug
Therapeutic Area: Rare Diseases and Disorders Product Name: RZ358
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
RZ358 is a fully human monoclonal antibody that works downstream from the pancreas and instead binds to a unique allosteric site on insulin receptors in the liver, fat, and muscle. It is under phase 3 trials for Congenital Hyperinsulinism.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
RZ358 is a fully human monoclonal antibody that works downstream from the pancreas and instead binds to a unique allosteric site on insulin receptors in the liver, fat, and muscle. It is under phase 3 clinical development for the treatment of Congenital Hyperinsulinism.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
RZ402 is a selective and potent plasma kallikrein inhibitor (PKI). It is being developed as a potential oral therapy for the chronic treatment of diabetic macular edema DME.
Lead Product(s): RZ402
Therapeutic Area: Ophthalmology Product Name: RZ402
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
RZ358 is a human monoclonal antibody that binds to a unique allosteric site on insulin receptors in the liver, fat, and muscle being investigated for the treatment of Congenital Hyperinsulinism.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
RZ358 is a human monoclonal antibody that binds to a unique allosteric site on insulin receptors in the liver, fat, and muscle being investigated for the treatment of Congenital Hyperinsulinism.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
RZ402 is a selective and potent PKI being developed as a potential once-daily oral therapy for the chronic treatment of DME. By inhibiting the formation of kallikrein, RZ402 is designed to block downstream bradykinin production.
Lead Product(s): RZ402
Therapeutic Area: Ophthalmology Product Name: RZ402
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Rezolute intends to use the net proceeds from the offering to fund the continued activities for development of RZ358 for Congenital Hyperinsulinism and RZ402 for Diabetic Macular Edema and other pipeline development, and for working capital and general corporate purposes.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $122.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2022
Details:
Rezolute intends to use the net proceeds from these offerings to fund the continued activities for development of RZ358 for Congenital Hyperinsulinism and RZ402 for Diabetic Macular Edema and other pipeline development, working capital, and general corporate purposes.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 01, 2022
Details:
Results are Phase 3 enabling and demonstrate the potential for RZ358, a human monoclonal antibody to be used as a monotherapy as well as a potential universal therapy for all forms of hyperinsulinism.
Lead Product(s): RZ358
Therapeutic Area: Genetic Disease Product Name: RZ358
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
